














httpPredictive scoring model of mortality after surgical
or endovascular revascularization in patients with
critical limb ischemia
Tatsuya Shiraki, MD,a Osamu Iida, MD,a Mitsuyoshi Takahara, MD, PhD,b Shin Okamoto, MD,a
Ikurou Kitano, MD, PhD,c Yoshihiko Tsuji, MD, PhD,c Hiroto Terashi, MD, PhD,d and
Masaaki Uematsu, MD, PhD,a Hyogo and Osaka, Japan
Objective: The latest guideline points to life expectancy of <2 years as the main determinant in revascularization modality
selection (bypass surgery [BSX] or endovascular therapy [EVT]) in patients with critical limb ischemia (CLI). This study
examined predictors and a predictive scoring model of 2-year mortality after revascularization.
Methods: We performed Cox proportional hazards regression analysis of data in a retrospective database, the Bypass and
Endovascular therapy Against Critical limb ischemia from Hyogo (BEACH) registry, of 459 consecutive CLI patients
who underwent revascularization (396 EVT and 63 BSX cases between January 2007 and December 2011) to determine
predictors of 2-year mortality. The predictive performance of the score was assessed with the area under the time-
dependent receiver operating characteristic curve.
Results: Of459CLI patients (mean age, 726 10 years; 64%male; 49%nonambulatory status, 68%diabetesmellitus, 47% on
regular dialysis, and18% rest pain and82% tissue loss as treatment indication), 84 diedwithin 2 years after revascularization.
In amultivariate model, age >75 years (hazard ratio [HR], 1.77; 95% conﬁdence interval [CI], 1.10-2.85), nonambulatory
status (HR, 5.32; 95% CI, 2.96-9.56), regular dialysis (HR, 1.90; 95% CI, 1.10-3.26), and ejection fraction <50% (HR,
2.49; 95% CI, 1.48-4.20) were independent predictors of 2-year mortality. The area under the time-dependent receiver
operating characteristic curve for the developed predictive BEACH score was 0.81 (95% CI, 0.76-0.86).
Conclusions: Predictors of 2-year mortality after EVT or BSX in CLI patients included age >75 years, nonambulatory
status, regular dialysis, and ejection fraction <50%. The BEACH score derived from these predictors allows risk strati-
ﬁcation of CLI patients undergoing revascularization. (J Vasc Surg 2014;60:383-9.)Revascularization is an optimal treatment for patients
with critical limb ischemia (CLI).1 In 2005, the BASIL
(Bypass vs Angioplasty in Severe Ischaemia of the Leg) in-
vestigators reported similar 2-year main clinical outcomes
(overall survival and amputation-free survival) after random-
ization to angioplasty-ﬁrst or bypass-ﬁrst revascularization
strategies.2 In 2010, they ﬁnally concluded that beyond
2 years after revascularization, there appeared to be a beneﬁt
for open bypass surgery (BSX).3 However, the predictors of
2-year mortality after endovascular therapy (EVT) or BSX
were not systematically examined.
Several predictive scoring models for outcomes in CLI
patients have been reported.4-6 The FINNVASC score
evaluated 30-day amputation-free survival in CLI patientsthe Kansai Rosai Hospital Cardiovascular Center, Hyogoa; the
epartment of Metabolic Medicine, Osaka University Graduate School
Medicine, Osakab; the Department of Surgery, Shinsuma General
ospital, Hyogoc; and the Department of Plastic Surgery, Kobe Univer-
y of Medicine, Hyogo.d
or conﬂict of interest: none.
rint requests: Tatsuya Shiraki, MD, Kansai Rosai Hospital Cardiovascu-
r Center, 3-1-69 Inabasou, Amagasaki, Hyogo 660-8511, Japan
-mail: Shiraki.tatsuya@gmail.com).
editors and reviewers of this article have no relevant ﬁnancial relationships
disclose per the JVS policy that requires reviewers to decline review of any
anuscript for which they may have a conﬂict of interest.
-5214/$36.00
yright  2014 by the Society for Vascular Surgery.
://dx.doi.org/10.1016/j.jvs.2014.02.059after infrainguinal surgical revascularization.4 PREVENT
III predicts 1-year amputation-free survival in CLI patients
after infrainguinal bypass with autogenous vein.5 The
BASIL survival prediction model assessed death at 6, 12,
and 24 months after EVT or BSX for severely ischemic
limbs6 and reported comparison of area under the receiver
operating characteristic (ROC) curves for BASIL, FINN-
VASC, and PREVENT III scores.7 At 2 years after revas-
cularization, the area under the curve for BASIL,
FINNVASC, and PREVENT III scores was 0.66, 0.53,
and 0.62, respectively,7 ie, clinically insufﬁcient to estimate
2-year mortality after revascularization for CLI patients.
Therefore, the current investigation was aimed at deter-
mining a precise and easy-to-use score to prognosticate
2-year survival in a population of CLI patients selected to
undergo EVT or BSX.
METHODS
Patients. Analysis in this study was based on data
extracted from a two-center (Kansai Rosai Hospital and
Shinsuma General Hospital) database, namely, the Bypass
and Endovascular therapy Against Critical limb ischemia
from Hyogo (BEACH) registry, including all 459 consec-
utive CLI patients (Rutherford class 4-6) who underwent
revascularization between January 2007 and December
2011. One limb was included per enrolled patient. All data
were entered at the time of ﬁrst admission, and the registry
was updated periodically with patient follow-up data up to383
Fig 1. Initial treatment of patients with critical limb ischemia (CLI). Bypass surgery (BSX) was conducted in 13.7%
(63 of 459) and endovascular therapy (EVT) in 86.3% (396 of 459). BP, Bypass; ePTFE, expanded polytetraﬂuoro-
ethylene; POP, popliteal; SFA, superﬁcial femoral artery.
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vascular or surgical revascularization were deﬁned as those
with severe comorbidities and impairment at the functional
(bedridden with intractable rest pain), cognitive (dementia
not requiring institutionalization), or social (no family or
professional career) level and those who refused revascu-
larization. These patients were excluded from analysis
before angiographic assessment because of the particular
challenges they pose for follow-up and for assessment and
interpretation of late consequences of treatment. The study
protocol was developed in accordance with the Declaration
of Helsinki and approved by the ethics committee of each
participating hospital. All patients gave written informed
consent before revascularization.
Study protocol. Brieﬂy, ankle-brachial index (ABI) and
skin perfusion pressure (SPP) were used to assess lower limb
hemodynamics. A group of vascular specialists including
vascular surgeons and radiologists judged whether EVT or
BSX was indicated for each patient. According to the Amer-
ican Heart Association guidelines, it is reasonable to perform
EVT as the initial procedure to improve distal blood ﬂow in
patients with limb-threatening lower extremity ischemia and
an estimated life expectancy of 2 years or less when an
autogenous vein conduit is not available. BSX is the reasonable
choice when estimated life expectancy ismore than 2 years and
an autogenous vein conduit is available.8 Life expectancy of
more than 2 years was decided at the physician’s discretion.
After informed consent was obtained, the revascularization
strategy was decided on the basis of the guidelines detailedbefore and the patient’s preference. In EVT, a primary stent-
ing strategy was used for aortoiliac lesions, whereas a provi-
sional stenting strategy was used for femoropopliteal lesions.
In femoropopliteal lesions, angioplasty was initially performed
with an optimally sized balloon. If the result after balloon
angioplasty was suboptimal, a nitinol stent (S.M.A.R.T.;
Cordis J&J, Miami, Fla) was implanted. For infrapopliteal
lesions, balloon angioplasty was repeatedly performed with an
optimally sized balloon. A>200-mm-length balloon (Shiden,
Kaneka Medix Corporation, Osaka, Japan; or Amphirion,
Medtronic, Minneapolis, Minn) was commonly used, and
balloon inﬂation was held at nominal pressure for at least
180 seconds to avoid ﬂow-limiting dissection. Dual anti-
platelet therapy (aspirin at 100 mg/d and ticlopidine at
200 mg/d or cilostazol at 200 mg/d) was started at least
1week before EVT and continued lifelong.Medical treatment
selection was left to the physician’s discretion.
BSX was performed by standard bypass techniques, and
autogenous vein graft was routinely used. Postprocedural
medication prescription followed local clinical practice.
Follow-up protocol. Study participants were fol-
lowed up in prospective visits at 1, 3, 6, 12, and 24 months
after BSX or EVT. Each patient was routinely assessed for
ischemic symptoms, ABI, SPP (SensiLase PAD 3000;
Väsamed, Eden Prairie, Minn), and duplex ultrasound
features as well as for wound condition. The indication
for repeated revascularization was clinically driven by
delayed wound healing or rest pain recurrence. Standard
criteria for repeated revascularization in this study were
Table I. Baseline characteristics
Overall (N ¼ 459) BSX (n ¼ 63) EVT (n ¼ 396) P
Patient status
Age, years 72 6 10 70 6 8 72 6 10 .14
Male gender 64.0% (294) 73.0% (46) 62.6% (248) .11
BMI 21 6 3 21 6 3 21 6 3 .72
BMI <18.5 22.4% (103) 22.2% (14) 22.4% (89) .47
Nonambulatory status 49.6% (228) 36.5% (23) 51.8% (205) .02
Diabetes mellitus 68.1% (313) 71.4% (45) 67.7% (268) .55
Regular dialysis 46.8% (215) 33.3% (21) 49.0% (194) .02
Coronary artery disease 41.1% (189) 44.4% (28) 40.7% (161) .57
Ejection fraction, % 62 6 12 64 6 12 61 6 12 .66
Ejection fraction <50% 15.6% (72) 12.6% (8) 16.1% (64) .48
Cerebrovascular disease 22.2% (102) 31.7% (20) 20.7% (82) .05
Limb status
Tissue loss 81.6% (375) 82.5% (52) 81.6% (323) .85
Isolated BTK artery disease 39.4% (181) 28.6% (18) 41.2% (163) .06
Laboratory data
Median CRP level, mg/dL 0.9 0.9 0.9 .65
Hematocrit, % 33 6 5 34 6 5 32 6 5 .68
Hematocrit #30% 31.3% (144) 28.5% (18) 31.8% (126) .19
Albumin level, g/dL 3.4 6 0.6 3.3 6 0.5 3.4 6 0.6 .54
Medication
Aspirin 85.6% (393) 76.2% (48) 88.2% (345) <.01
Thienopyridine 27.6% (127) 17.5% (11) 42.5% (116) <.01
Cilostazol 52.7% (242) 33.3% (21) 56.5% (221) <.01
Warfarin 26.1% (120) 77.8% (49) 17.9% (71) <.01
Statin 18.3% (84) 12.7% (8) 19.2% (76) .05
ACE inhibitor/ARB 32.5% (149) 42.9% (27) 30.8% (122) <.01
b Blocker 15.0% (69) 17.5% (11) 14.6% (58) .52
ACE, Angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; BSX, bypass surgery; BTK, below-the-knee;
CRP, C-reactive protein; EVT, endovascular therapy.
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duplex ultrasound imaging.
Deﬁnitions. A critically ischemic limb was deﬁned ac-
cording to the TransAtlantic Inter-Society Consensus II
guideline. When deﬁnition-required measurements could
not be obtained because of intractable rest pain or a
noncompressible artery with severe calciﬁcation, SPP was
measured instead of toe or ankle pressure; an SPP <40 mm
Hg was deﬁned as indicating a critically ischemic limb.
Nonambulatory status was deﬁned as wheelchair bound or
bedridden. Coronary artery disease and cerebrovascular
disease were deﬁned as the presence of symptoms or past
history of any intervention or infarction.
Statistical analysis. Data are expressed as mean and
standard deviation for continuous variables or as percentage
for dichotomous variables, unless otherwise mentioned.
Prognostic outcomes were assessed with the Kaplan-Meier
method and between-group differences with the log-rank
test. Univariate and multivariate Cox proportional hazards
regression models were used to investigate the unadjusted
and adjusted association of preoperative characteristics with
2-year mortality, respectively. Hazard ratios (HRs) and 95%
conﬁdence intervals (CIs) are reported. The variables with
statistical signiﬁcance in the multivariate model were
determined as the independent risk factors for the outcome.
Risk stratiﬁcation analysis was subsequently conducted by a
simple score based on the number of the independent riskfactors present. The predictive performance of the score was
assessed by time-dependent ROC curve analyses.9 A P value
of < .05 was considered signiﬁcant. Statistical analyses were
performedwith SPSS version 15.0J (SPSS Inc, Chicago, Ill),
except for the time-dependent ROC curve analysis, which
was performed by R.
RESULTS
The initial treatment strategy for the 459 CLI patients is
summarized in Fig 1. BSX and EVT were conducted in
13.7% (63 of 459) and 86.3% (396 of 459) of patients,
respectively. Baseline characteristics are shown in Table I.
Mean age was 72 6 10 years; 294 patients (64%) were
male; and mean body mass index (BMI) was 21 6 3, with
22.4% of patients being underweight (BMI <18.5).
Notable comorbidities included diabetes mellitus (68.1%;
313 of 459), followed by regular dialysis dependence
(46.8%; 215 of 459) and coronary artery disease (41.1%;
189 of 459). Regarding limb condition before revasculariza-
tion, mean ABI and SPP were 0.656 0.26 and 286 16mm
Hg, respectively (not shown in table). The fact that almost
half the patients studied were on dialysis, which is associated
with calciﬁcation, may account for the falsely high ABI. Tis-
sue loss was observed in 81.6% of patients (375 of 459), and
181 patients (39.4%) had isolated below-the-knee artery dis-
ease. Compared with the BSX group, the EVT group had a
higher prevalence of nonambulatory status (36.5% vs 51.8%:
Fig 2. Survival rate in bypass surgery (BSX) group (n ¼ 63) and
endovascular therapy (EVT) group (n ¼ 396). The rates of survival
after BSX (blue line, n ¼ 63) and EVT (red line, n ¼ 396) stra-
tegies did not differ signiﬁcantly at 2 years (77% vs 74%; P ¼ .33).
SE, Standard error.
Fig 3. Cause of death within 2 years after revascularization
(n ¼ 84). The most prevalent cause was cardiac death (38%; 32 of
84), followed by infection (25%; 21 of 84). Almost half of the
patients were dead because of cardiovascular events.
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laboratory testing, overall median C-reactive protein level,
mean hematocrit, and mean albumin level were 0.9 mg/dL,
33% 6 5%, and 3.4 6 0.6 g/dL, respectively, and levels
were not signiﬁcantly different between treatment modality
groups. Antiplatelet therapy was prescribed more often for
the EVT group than for the BSX group. On the other
hand, warfarin was highly prescribed for patients treated
with BSX compared with those in the EVT group. Statins
were prescribed in 18.3% patients with CLI; however, they
were prescribed to only 1.8% of patients in the BSX group.
Angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers and b-blockers were prescribed to 32.5%
and 15.0% of patients, respectively. Forty-two percent of
patients (194 of 459) were followed up for 2 years, with
84 deaths during that period.
Prognosis of CLI patients after revascularization.
Overall survival rate at 2 years after revascularization was
74%. Fig 2 shows that the 2-year survival rate was similar
for BSX and EVT strategies (77% vs 74%; P ¼ .33). Causes
of death within 2 years after revascularization are shown in
Fig 3. The most prevalent cause of death was cardiac (38%;
32 of 84), followed by infection (25%; 21 of 84). In terms
of vascular death (11%; 9 of 84), ﬁve patients died sec-
ondary to bowel ischemia and four to stroke. Severe
bleeding occurred in 7% (6 of 84) of those dying within
2 years after revascularization; upper gastrointestinal
bleeding was observed in four cases, two of which were
complicated by puncture bleeding. One death was associ-
ated with hemorrhagic shock secondary to trauma. Pneu-
monia accounted for the largest proportion (67%; 14 of
21) of deaths by infection in this study; sepsis of unknown
etiology accounted for the remaining seven cases. Periop-
erative (<30 days) mortality after revascularization was 4%
(18 cases). The causes of perioperative death werecardiovascular event (33%; 6 of 18), infection (22%; 4 of
18), gastrointestinal bleeding (11%; 2 of 18), bleeding
related to revascularization (11%; 2 of 18), bowel ischemia
(11%; 2 of 18), and stroke (11%; 2 of 18).
Predictors of survival within 2 years after EVT or
BSX. As shown in Table II, univariate analysis revealed
signiﬁcant association with 2-year mortality for the
following variables: age >75 years (HR, 1.63; 95% CI,
1.06-2.51; P ¼ .024), nonambulatory status (HR, 7.08;
95% CI, 4.03-12.4; P < .001), BMI <18.5 (HR, 2.04;
95% CI, 1.31-3.20; P ¼ .001), regular dialysis (HR, 2.58;
95% CI, 1.63-4.08; P < .001), and ejection fraction <50%
(HR, 3.25; 95% CI, 2.05-5.15; P < .001). In multivariate
analysis, age >75 years (HR, 1.77; 95% CI, 1.10-2.85; P ¼
.017), nonambulatory status (HR, 5.32; 95% CI, 2.96-
9.56; P < .001), regular dialysis (HR, 1.90; 95% CI,
1.10-3.26; P ¼ .019), and ejection fraction <50% (HR,
2.49; 95% CI, 1.48-4.20; P < .001) were independent risk
factors of 2-year mortality after revascularization.
Risk stratiﬁcation by the number of independent
predictors for 2-year mortality after revascularization.
Stratiﬁcation of patients based on the number of indepen-
dent risk factors present yielded three signiﬁcantly different
estimates for 2-year survival rate for low-, intermediate-,
and high-risk groups: 98%, 78%, and 29%, respectively
(P < .001 for each comparison; Fig 4). As shown in Fig 5,
the area under the time-dependent ROC curve was 0.81
(95% CI, 0.76-0.86).
DISCUSSION
In this study, we developed a predictive scoring model
using the BEACH registry database; predictive perfor-
mance of the score was highly associated with 2-year mor-
tality of CLI patients. The 2-year overall survival rate after
revascularization for CLI was 74%. Age >75 years, nonam-
bulatory status, regular dialysis, and ejection fraction <50%
were the independent predictors of 2-year mortality after
revascularization for CLI.
The BASIL investigators developed a model to predict
death at 6, 12, and 24 months after EVT or BSX6 on the
Table II. Univariate and multivariate analysis: Predictors of 2-year mortality after revascularization in CLI patients
Factors
Univariate analysis Multivariate analysis (model 1) Multivariate analysis (model 2)
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age >75 years 1.63 (1.06-2.51) .024 1.77 (1.10-2.85) .017 1.80 (1.14-2.83) .010
Male 1.01 (0.64-1.58) .955 0.89 (0.56-1.44) .658 e
Tissue loss 1.76 (0.93-3.32) .075 0.96 (0.49-1.91) .927 e
Isolated BTK disease 1.14 (0.73-1.75) .552 1.33 (0.83-2.14) .232 e
Nonambulatory status 7.08 (4.03-12.4) <.001 5.32 (2.96-9.56) <.001 5.66 (3.21-10.0) <.001
BMI <18.5 2.04 (1.31-3.20) .001 1.35 (0.84-2.18) .207 e
Hematocrit #30% 1.52 (0.97-2.38) .063 1.12 (0.69-1.80) .638 e
Regular dialysis 2.58 (1.63-4.08) <.001 1.90 (1.10-3.26) .019 2.15 (1.31-3.54) .002
Diabetes mellitus 0.92 (0.59-1.44) .732 0.87 (0.54-1.39) .571 e
Coronary artery disease 1.50 (0.97-2.30) .062 1.09 (0.66-1.80) .727 e
Ejection fraction <50% 3.25 (2.05-5.15) <.001 2.49 (1.48-4.20) <.001 2.37 (1.47-3.83) <.001
Cerebrovascular disease 1.24 (0.75-2.03) .388 1.10 (0.65-1.84) .718 e
BMI, Body mass index; BTK, below-the-knee; CI, conﬁdence interval; HR, hazard ratio.
Fig 4. Risk stratiﬁcation by the number of risk factors after
multivariate analysis. Stratiﬁcation of the patients by the number of
risk factors yielded three signiﬁcantly different estimates for 2-year
survival: low risk, 97% (blue line, n ¼ 70); medium risk, 77% (green
line, n ¼ 317); and high risk, 29% (red line, n ¼ 72) (P < .001 for
each comparison). SE, Standard error.
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tration, number of ankle pressure measurements detectable,
maximum ankle pressure measured, history of myocardial
infarction or angina, history of stroke or transient ischemic
attack, below-knee Bollinger angiogram score, BMI, and
smoking status. Although the BASIL score requires many
variables, predictive ability for 2-year mortality after revascu-
larization was not high (area under the curve ¼ 0.66 [0.59-
0.74]).7 Moreover, 2-year mortality cannot be estimated by
the Bollinger angiogram score without angiography.
Data from the FINNVASC and PREVENT III registry
have informed two risk-scoring models for amputation-free
survival after BSX in CLI patients.4,5 The FINNVASC reg-
istry demonstrated that diabetes mellitus, coronary arterydisease, foot gangrene, and urgent operation were inde-
pendent predictors of 30-day postoperative mortality or
major amputation in patients undergoing infrainguinal sur-
gical revascularization.4 In the PREVENT registry, dialysis,
presence of tissue loss, age >75 years, hematocrit <30, and
advanced coronary artery disease were signiﬁcant predictors
for amputation-free survival in the multivariate model.5
Calculation of a PREVENT III risk score was useful for
clinical decision-making in the CLI population.5 However,
FINNVASC and PREVENT scoring models were not
meant to assess 2-year mortality in CLI patients.7
We developed a predictive model for 2-year mortality
based on the four independent mortality predictors identi-
ﬁed in this study, and the result was consistent with that of
previous reports.4-6 On the other hand, several predictors
known to be associated with amputation-free survival
were not independently associated with 2-year mortality
in this study.
Advanced age of the patient is a common concern
because of the increasing number of comorbidities.10 Octo-
genarians with CLI treated by surgical bypass had a ﬁvefold
higher 1-year mortality rate than that of nonoctogenar-
ians.11 Age >75 years also was an independent predictor
for 2-year mortality in our study as it was in PREVENT III.
Hemodialysis patients with CLI have signiﬁcantly
poorer 5-year survival than nonhemodialysis ones do
(24.3% vs 48.0%; P < .001).12 Diabetes mellitus has been
shown to be one of the chief atherosclerotic risk factors for
CLI patients. In this study, regular dialysis was signiﬁcantly
associated with 2-year mortality, whereas diabetes mellitus
was not.13Diabetesmellitus has been reported as a risk factor
for amputation-free survival after BSX4but not for survival.14
Diabetes might be relevant to amputation-free survival
because of its impact on lower limb prognosis.
An active lifestyle reduces the risk of cardiovascular dis-
ease and consequently has a beneﬁcial effect on mortality
in a healthy elderly population.15 Nonambulatory CLI
patients could not perform sufﬁcient exercise, leading to
poorer outcomes compared with ambulatory CLI patients.
Fig 5. Time-dependent receiver operating characteristic (ROC) curve of the BEACH score. The BEACH score is
deﬁned as the sum of multivariable factors (0-4 points: age >75 years, nonambulatory status, regular dialysis, and
ejection fraction <50%) associated with 2-year mortality. The area under the curve (AUC) was 0.81 (95% conﬁdence
interval [CI], 0.76-0.86).
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cant factor associated with mortality (hazard ratio, 5.32).
Ejection fraction <50% from ultrasound examination
was a strong independent predictor of 2-year mortality
after revascularization. Cardiovascular events account for
50% of all causes of death after revascularization in CLI
patients. The proportion of deaths secondary to acute cor-
onary syndrome is lower than that of chronic heart failure
and arrhythmia. Several reports have mentioned past his-
tory of coronary artery disease as one of the predictors in
CLI patients.4-6 Left ventricular dysfunction, however,
was more strongly relevant to prognosis than was past his-
tory of coronary artery disease in our study.
FINNVASC and PREVENT III predictive methods
suggested an association between presence of tissue loss
and amputation-free survival. However, studies of midterm
outcomes after EVT have reported an association between
Rutherford criteria and amputation but not mortality.14
Likewise in this study, tissue loss was not a multivariate in-
dependent predictor of 2-year mortality.
The area under the time-dependent ROC curve for the
BEACH scoring model was as high as 0.81. A recent report
evaluated the predictive power of the BASIL, FINNVASC,
and PREVENT III models. The area under ROC curves
with use of BASIL, FINNVASC, and PREVENT to pre-
dict 2- year mortality was only 0.66 (0.59-0.74), 0.53
(0.45-0.62), and 0.63 (0.54-0.71), respectively.7 The
developed predictive scoring model from the BEACH reg-
istry was highly associated, compared with previous models,
with 2-year mortality in CLI patients after revascularization.
The characteristics of this developed predictive
scoring model were simple. Accuracy of this model was
estimated by area under the time-dependent ROC curve(0.81 [95% CI, 0.76-0.86]), which was not signiﬁcantly
different from those accounting for the relative strengths
of the four risk factors’ predictive power (0.82 [95% CI,
0.76-0.87]; P ¼ .499). From this result, we adopted the
simple scoring model; the ease of its calculation renders
it clinically useful.
Limitations. This was a retrospective analysis of regis-
try data. Only 42% of patients (194 of 459) were followed
up for 2 years after revascularization. The data in this study
were not separated into training and test data to develop
and to assess, respectively, validity of predictive models.
The current ﬁndings therefore should be externally vali-
dated in settings with similar sample characteristics. It re-
mains to be determined if the developed model can be
validated in the general population sampled independently
of revascularization treatment use. Construction of a
model in a random sample of the general population might
be warranted; patients without revascularization were
excluded, and the population of patients treated with pri-
mary amputation was not well examined. Only Japanese
patients, characterized by a high proportion of dialysis
dependence, were included in this study; therefore, it re-
mains to be seen whether this predictive model would
allow risk stratiﬁcation of CLI patients in other countries.
We did not collect information on the nature of tissue loss
(ulcer and gangrene). Information on medical therapy was
collected only after revascularization. We could not deter-
mine compliance, discontinuation, or other details of
medication use during the 2-year follow-up after revas-
cularization. The predictive power of the BEACH model
was not evaluated directly against that of any other scoring
model. Further evaluation of differences among prediction
models in CLI patients is warranted.
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Independent predictors of 2-year mortality after EVT
or BSX for CLI include age >75 years, nonambulatory sta-
tus, regular dialysis, and ejection fraction <50%. The pre-
dictive BEACH scoring model derived from these
independent predictors allows postrevascularization mor-
tality risk assessment in CLI patients.
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